Abstract
Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have